Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song(Peking University), Jun Zhu(Peking University), Kaiyang Ding(Anhui Provincial Hospital), Huilai Zhang(Shanxi Medical University), Pamela B. Allen(Emory University), Yue-Rong Shuang(Jiangxi Provincial Cancer Hospital), Dok Hyun Yoon(Ulsan College), Liqun Zou(Sichuan University), Jianqiu Wu(Jiangsu Cancer Hospital), Zhenfan Yang(SciencePharma (Poland)), Haiyan Yang(Zhejiang Cancer Hospital), Keshu Zhou(Zhengzhou University), Qingqing Cai(Sun Yat-sen University), Weili Zhao(Shanghai Institute of Hematology), Fernando Roncolato(St George Hospital), Miles Prince(Epworth Hospital), Hui Zhou(Hunan Cancer Hospital), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Luis Malpica(The University of Texas MD Anderson Cancer Center), Lie Lin(Hainan General Hospital), Sujun Gao(Jilin University), Hui Liu(Shanghai University), Wenyu Li(Shenyang Agricultural University), Yao Liu(Chongqing University), Liling Zhang(Union Hospital), Zhimin Zhai(Anhui Medical University), Fei Li(Xiamen Medical College), Jie Jin(First Affiliated Hospital Zhejiang University), Yaming Xi(First Hospital of Lanzhou University), Youngil Koh(Seoul National University Hospital), Zengjun Li(West China Medical Center of Sichuan University), Won-Seog Kim(Samsung Medical Center), Meifang Zheng
The Lancet Oncology
December 9, 2023
10.1016/s1470-2045(23)00589-2
Cited by 55

Related Papers

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403